ARCUS BIOSCIENCES INC (RCUS) — insider trading
Health Care · NYSE
A clinical-stage biotech developing first-in-class and best-in-class small molecules and antibodies for cancer immunotherapy, with lead HIF-2α inhibitor in late-stage trials.
As of 2026-07-23, no SEC Form 4 insider transactions — open-market buys or sells, awards, or option exercises — have been reported for ARCUS BIOSCIENCES INC (RCUS) in our data.
We ingest insider filings from SEC EDGAR; a company can have no recent ownership filings, or its filings may not yet be in our data. You can always check the primary source directly via the SEC link above, or see the full company profile.
More on ARCUS BIOSCIENCES INC: company profile · SEC filings · congressional trading · similar companies.
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR.